دورية أكاديمية
Clinical Conditions Targeted by OnabotulinumtoxinA in Different Ways in Medicine.
| العنوان: | Clinical Conditions Targeted by OnabotulinumtoxinA in Different Ways in Medicine. |
|---|---|
| المؤلفون: | Onan D; Department of Physiotherapy and Rehabilitation, Faculty of Heath Sciences, Yozgat Bozok University, Yozgat 66000, Turkey., Farham F; Department of Headache, Iranian Centre of Neurological Research, Neuroscience Institute, Tehran University of Medical Sciences, Tehran 1417653761, Iran., Martelletti P; School of Health, Unitelma Sapienza University of Rome, 00161 Rome, Italy. |
| المصدر: | Toxins [Toxins (Basel)] 2024 Jul 07; Vol. 16 (7). Date of Electronic Publication: 2024 Jul 07. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: MDPI Country of Publication: Switzerland NLM ID: 101530765 Publication Model: Electronic Cited Medium: Internet ISSN: 2072-6651 (Electronic) Linking ISSN: 20726651 NLM ISO Abbreviation: Toxins (Basel) Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: Basel : MDPI |
| مواضيع طبية MeSH: | Botulinum Toxins, Type A*/therapeutic use , Botulinum Toxins, Type A*/pharmacology, Humans ; Animals ; Acetylcholine Release Inhibitors/therapeutic use ; Pain/drug therapy ; Acetylcholine/metabolism ; Neuromuscular Agents/therapeutic use ; Neuromuscular Agents/pharmacology |
| مستخلص: | OnabotulinumtoxinA (BT-A) is used in different medical fields for its beneficial effects. BT-A, a toxin originally produced by the bacterium Clostridium botulinum, is widely known for its ability to temporarily paralyze muscles by blocking the release of acetylcholine, a neurotransmitter involved in muscle contraction. The literature continually reports new hypotheses regarding potential applications that do not consider blockade of acetylcholine release at the neuromuscular junction as a common pathway. In this opinion article, it is our aim to investigate the different pathway targets of BT-A in different medical applications. First of all, the acetylcholine effect of BT-A is used to reduce wrinkles for cosmetic purposes, in the treatment of urological problems, excessive sweating, temporomandibular joint disorders, obesity, migraine, spasticity in neurological diseases, and in various cases of muscle overactivity such as cervical dystonia, blepharospasm, and essential head tremor. In another potential pathway, glutamate A, CGRP, and substance P are targeted for pain inhibition with BT-A application in conditions such as migraine, trigeminal neuralgia, neuropathic pain, and myofascial pain syndrome. On the other hand, as a mechanism different from acetylcholine and pain mediators, BT-A is used in the treatment of hair loss by increasing oxygenation and targeting transforming growth factor-beta 1 cells. In addition, the effect of BT-A on the apoptosis of cancer cells is also known and is being developed. The benefits of BT-A applied in different doses to different regions for different medical purposes are shown in literature studies, and it is also emphasized in those studies that repeating the applications increases the benefits in the long term. The use of BT-A continues to expand as researchers discover new potential therapeutic uses for this versatile toxin. |
| References: | Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005 Dec;100(6):693-700. (PMID: 16301150) Plast Reconstr Surg. 2016 Nov;138(5):821e-829e. (PMID: 27391832) Int Ophthalmol Clin. 2005 Summer;45(3):25-37. (PMID: 15970764) Regul Pept. 2005 Mar 15;126(1-2):11-9. (PMID: 15620408) Toxicology. 2015 Sep 1;335:79-84. (PMID: 26169827) PLoS One. 2017 Apr 17;12(4):e0175028. (PMID: 28414728) Neurology. 1999 Nov 10;53(8):1850-3. (PMID: 10563638) Front Neurol. 2016 Mar 31;7:45. (PMID: 27064462) J Am Acad Dermatol. 2020 Dec;83(6):1838-1839. (PMID: 32339707) Front Neurol. 2023 Apr 06;14:1133390. (PMID: 37090974) World J Urol. 2024 Apr 6;42(1):218. (PMID: 38581447) Br J Dermatol. 2005 Feb;152(2):342-5. (PMID: 15727649) J Sex Med. 2019 Sep;16(9):1338-1343. (PMID: 31277970) Semin Neurol. 2004 Jun;24(2):155-63. (PMID: 15257512) J Am Acad Dermatol. 2019 Sep;81(3):657-666. (PMID: 30710604) Acta Dermatovenerol Croat. 2011;19(1):16-20. (PMID: 21489361) Eur Urol. 2011 Oct;60(4):784-95. (PMID: 21782318) Toxins (Basel). 2024 Apr 09;16(4):. (PMID: 38668609) Lancet. 2011 Feb 12;377(9765):557-67. (PMID: 21295846) J Neurosurg Sci. 2021 Oct;65(5):543-544. (PMID: 32989977) Toxins (Basel). 2020 Feb 18;12(2):. (PMID: 32085522) Toxins (Basel). 2013 May 21;5(5):1010-31. (PMID: 23698357) Biochem Pharmacol. 2000 Jun 1;59(11):1403-6. (PMID: 10751549) Acta Derm Venereol. 2024 Apr 09;104:adv24305. (PMID: 38590258) Medicine (Baltimore). 2023 Jul 1;102(S1):e32372. (PMID: 37499078) Neurology. 2009 Apr 28;72(17):1473-8. (PMID: 19246421) Dig Liver Dis. 2008 Aug;40(8):667-72. (PMID: 18420471) Toxins (Basel). 2020 May 04;12(5):. (PMID: 32375388) Pain. 2011 Oct;152(10):2204-2205. (PMID: 21764514) Br J Oral Maxillofac Surg. 2004 Jun;42(3):272-3. (PMID: 15121281) Medicine (Baltimore). 2017 Sep;96(39):e8133. (PMID: 28953646) Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):3200-5. (PMID: 10077661) Toxins (Basel). 2022 Nov 09;14(11):. (PMID: 36356024) Neurology. 2016 May 10;86(19):1818-26. (PMID: 27164716) Rev Paul Pediatr. 2024 Mar 25;42:e2023093. (PMID: 38537033) Anesthesiology. 2005 Aug;103(2):377-83. (PMID: 16052120) Dermatol Surg. 2012 Nov;38(11):1794-803. (PMID: 23106853) J Neurol. 2004 Feb;251 Suppl 1:I1-7. (PMID: 14991335) Anesth Analg. 2011 Jan;112(1):228-35. (PMID: 21081780) Prostate. 2009 Aug 1;69(11):1143-50. (PMID: 19399787) J Biol Chem. 2004 Jun 11;279(24):25665-72. (PMID: 15066994) J Sex Med. 2017 Feb;14(2):177-178. (PMID: 28161074) Clin Nutr. 2021 Apr;40(4):1834-1842. (PMID: 33092901) Toxins (Basel). 2019 Aug 05;11(8):. (PMID: 31387301) Headache. 2003 Jul-Aug;43 Suppl 1:S16-24. (PMID: 12887390) Curr Atheroscler Rep. 2002 Nov;4(6):448-53. (PMID: 12361492) Toxins (Basel). 2015 Aug 14;7(8):3127-54. (PMID: 26287242) Dev Med Child Neurol. 1998 Aug;40(8):520-7. (PMID: 9746004) Obes Rev. 2012 Apr;13(4):388-92. (PMID: 22151906) Neurotoxicology. 2005 Oct;26(5):785-93. (PMID: 16002144) Paediatr Drugs. 2019 Aug;21(4):261-281. (PMID: 31257556) J Microbiol Biotechnol. 2012 Jan;22(1):50-7. (PMID: 22297219) World Neurosurg. 2021 Feb;146:e1287-e1292. (PMID: 33285336) Clin Endosc. 2017 Jan;50(1):11-16. (PMID: 28147471) Eur J Neurol. 2011 Jan;18(1):5-18. (PMID: 20482602) Medicine (Baltimore). 2023 Jul 1;102(S1):e32764. (PMID: 37499084) Urologia. 2012 Apr-Jun;79(2):135-41. (PMID: 22610840) Headache. 2017 Jan;57(1):109-125. (PMID: 27910097) Semin Neurol. 2016 Feb;36(1):29-33. (PMID: 26866493) J Headache Pain. 2023 Dec 6;24(1):164. (PMID: 38057728) J Physiol Paris. 2002 Jan-Mar;96(1-2):105-13. (PMID: 11755789) Toxins (Basel). 2022 Dec 30;15(1):. (PMID: 36668849) Front Neurol. 2017 Feb 24;8:35. (PMID: 28286494) Cochrane Database Syst Rev. 2017 Mar 02;3:CD006499. (PMID: 28253424) Medicine (Baltimore). 2023 Jul 1;102(S1):e32363. (PMID: 37499087) Urology. 2022 Dec;170:5-13. (PMID: 36115427) Nat Clin Pract Urol. 2008 Jun;5(6):319-28. (PMID: 18461049) Headache. 2004 Jan;44(1):35-42; discussion 42-3. (PMID: 14979881) Pain. 2004 Jan;107(1-2):125-33. (PMID: 14715398) Cephalalgia. 2012 Nov;32(15):1154-5; author reply 1156-7. (PMID: 22990690) Gastrointest Endosc. 2016 Feb;83(2):478. (PMID: 26773642) Head Neck. 2004 Jan;26(1):39-45. (PMID: 14724905) J Child Orthop. 2008 Feb;2(1):29-35. (PMID: 19308600) Toxins (Basel). 2020 Jan 05;12(1):. (PMID: 31948115) Drugs. 2019 Feb;79(2):143-160. (PMID: 30623347) Toxins (Basel). 2022 Aug 24;14(9):. (PMID: 36136520) J Oral Maxillofac Res. 2020 Jun 30;11(2):e2. (PMID: 32760475) J Headache Pain. 2016 Dec;17(1):112. (PMID: 27957623) J Headache Pain. 2023 Aug 3;24(1):102. (PMID: 37537578) J Cell Sci. 2007 Aug 15;120(Pt 16):2864-74. (PMID: 17666428) Asian Pac J Cancer Prev. 2013;14(2):891-4. (PMID: 23621257) Dermatol Surg. 2022 Nov 1;48(11):1191-1197. (PMID: 36342250) Pain. 2006 Jun;122(3):315-325. (PMID: 16677761) J Headache Pain. 2017 Dec;18(1):66. (PMID: 28667550) N Engl J Med. 2023 Nov 9;389(19):1753-1765. (PMID: 37937777) Exp Dermatol. 2004;13 Suppl 4:27-30. (PMID: 15507109) Neurology. 2005 Oct 25;65(8):1306-8. (PMID: 16247065) J Urol. 2011 Sep;186(3):965-70. (PMID: 21791356) Biomed Res Int. 2020 Aug 04;2020:1501893. (PMID: 32802833) Mov Disord. 2004 Mar;19 Suppl 8:S2-6. (PMID: 15027048) Curr Opin Pharmacol. 2009 Jun;9(3):326-35. (PMID: 19394272) BMC Neurol. 2019 May 11;19(1):96. (PMID: 31078139) Exp Dermatol. 2015 Apr;24(4):285-9. (PMID: 25644735) Pain Pract. 2008 Jul-Aug;8(4):269-76. (PMID: 18503628) Pain. 2005 Nov;118(1-2):170-5. (PMID: 16202527) Pain Med. 2010 Dec;11(12):1827-33. (PMID: 21134121) Appl Microbiol Biotechnol. 2022 Jan;106(2):485-495. (PMID: 34951660) Pharmaceuticals (Basel). 2024 Feb 28;17(3):. (PMID: 38543096) Pain. 2006 Nov;125(1-2):82-8. (PMID: 16750294) Toxins (Basel). 2017 Aug 24;9(9):. (PMID: 28837075) J Neurol Neurosurg Psychiatry. 2015 Apr;86(4):393-7. (PMID: 25288608) J Urol. 1996 Mar;155(3):1023-9. (PMID: 8583552) Pain. 2009 Jan;141(1-2):60-9. (PMID: 19004549) J Neural Transm (Vienna). 2008;115(4):567-73. (PMID: 17557128) Toxins (Basel). 2023 Dec 06;15(12):. (PMID: 38133189) Toxins (Basel). 2023 Jan 17;15(2):. (PMID: 36828401) Neurology. 1995 Apr;45(4):822-4. (PMID: 7723978) Neurobiol Dis. 2012 Dec;48(3):367-78. (PMID: 22820141) J Headache Pain. 2024 Feb 2;25(1):14. (PMID: 38308209) Skin Res Technol. 2024 Apr;30(4):e13696. (PMID: 38602262) Toxins (Basel). 2023 Jun 09;15(6):. (PMID: 37368692) J Dent (Shiraz). 2017 Sep;18(3):157-164. (PMID: 29034269) Noro Psikiyatr Ars. 2013 Aug;50(Suppl 1):S36-S40. (PMID: 28360582) Neuropharmacology. 2018 Aug;138:257-266. (PMID: 29906413) Ann Neurol. 2008 Sep;64(3):274-83. (PMID: 18546285) Eur Urol. 2012 Sep;62(3):507-14. (PMID: 22236796) J Neurol. 2014 Oct;261(10):1857-65. (PMID: 24413637) Rev Infect Dis. 1979 Jul-Aug;1(4):701-19. (PMID: 399378) J Physiol. 2013 Aug 15;591(16):3935-47. (PMID: 23774277) J Am Acad Dermatol. 2020 Apr;82(4):969-979. (PMID: 31811879) |
| فهرسة مساهمة: | Keywords: CGRP; OnabotulinumtoxinA; chronic migraine; excessive sweating; hair loss; spasticity; trigeminal neuralgia; wrinkle |
| المشرفين على المادة: | EC 3.4.24.69 (Botulinum Toxins, Type A) EC 3.4.24.69 (onabotulinum toxin A) 0 (Acetylcholine Release Inhibitors) N9YNS0M02X (Acetylcholine) 0 (Neuromuscular Agents) |
| تواريخ الأحداث: | Date Created: 20240726 Date Completed: 20240726 Latest Revision: 20240728 |
| رمز التحديث: | 20240728 |
| مُعرف محوري في PubMed: | PMC11280961 |
| DOI: | 10.3390/toxins16070309 |
| PMID: | 39057949 |
| قاعدة البيانات: | MEDLINE |
Full Text Finder | تدمد: | 2072-6651 |
|---|---|
| DOI: | 10.3390/toxins16070309 |